Foundayo 5.5mg tablets contain orforglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Foundayo is a prescription-only medicine used for weight management in eligible adults and to improve glycaemic control in adults with insufficiently controlled type 2 diabetes, according to its authorised product information.
Orforglipron acts on GLP-1 receptors involved in appetite regulation and glucose metabolism. For weight management, treatment is used alongside a reduced-calorie diet and increased physical activity. The 5.5mg strength should be used only as directed by the prescribing healthcare professional and in accordance with the authorised dose-escalation schedule.Foundayo provides an oral treatment option for eligible adults requiring medical management of weight or type 2 diabetes. Its active ingredient, orforglipron, acts on GLP-1 receptors involved in appetite regulation and glucose metabolism.
The prescribed strength and treatment schedule depend on the individual’s clinical circumstances, response and tolerability. Patients should follow their prescriber’s instructions and should not change their dose independently.
Weight management: Used alongside a reduced-calorie diet and increased physical activity in eligible adults, according to the authorised indication.
Type 2 diabetes: Used alongside diet and exercise to improve blood glucose control in eligible adults with insufficiently controlled type 2 diabetes, in accordance with the authorised product information.
Foundayo contains orforglipron, a non-peptide GLP-1 receptor agonist. It activates GLP-1 receptors involved in appetite regulation and glucose metabolism.
Its effects include reducing food intake, supporting weight reduction and improving blood glucose control. It may also delay gastric emptying.
Foundayo should be used only as prescribed and alongside the lifestyle measures recommended by the treating healthcare professional.
